SOT Annual Meeting and ToxExpo 2025

Certara offers advanced toxicology solutions to predict, assess, and mitigate safety risks in drug development. Using technologies like Quantitative Systems Toxicology (QST) and physiologically based pharmacokinetic (PBPK) modeling, we help foresee toxicological outcomes such as hepatotoxicity, cardiotoxicity, and immunotoxicity.

Key Offerings:

1. Translational Modeling: Bridges preclinical data to human predictions.
2. Toxicokinetic (TK) Analysis: Establishes safety margins.
3. Complex Therapies: Specializes in biologics and gene therapies.
4. Virtual Tissue Models: Evaluates off-target effects, drug-drug interactions (DDIs), and immunogenicity risks.
5. 初期の開発: Specialized early development services designed to optimize this critical phase of drug development. Our approach combines cutting-edge science with extensive experience to provide you with a clear, strategic roadmap. From preclinical testing to early clinical trials, owe help streamline the process and address potential issues before they become major hurdles.

Featured Tools:

1. SEND Explorer: A web-based application for managing nonclinical study data, offering advanced capabilities for viewing, summarizing, and visualizing data in the SEND format to aid decision-making.
2. Secondary Intelligence: Predicts off-target adverse events using screening data, helping to identify potential safety risks and prioritize compounds based on safety profiles.

We support all stages of drug development and assist with regulatory submissions (INDs, NDAs, BLAs). Our consulting and training services help navigate regulatory challenges and optimize safety studies.

Join Us at SOT! Explore our vendor-hosted presentations and experience live demos of SEND Explorer and Secondary Intelligence. Stay tuned for updates!

Additional Resources

• ニーズに応じてカスタマイズ可能な毒性評価サービス
• Secondary Intelligence Fact Sheet
• ToxStudio®: Secondary Intelligence™ に関するよくあるご質問
• サターラ の戦略的早期開発ソリューション
• SEND Explorer – Product Family Fact Sheet
• 前臨床開発医薬品開発 支援サービス